Tazobactum%25252525252525252525252525252525252525252525252525252520piperacillin

# Piperacillin-Tazobactam ## Overview Piperacillin-tazobactam is a combination penicillin-class antibiotic with a beta-lactamase inhibitor. Piperacillin is an extended-spectrum penicillin that inhibits bacterial cell wall synthesis. Tazobactam inhibits most clinically significant beta-lactamases. ## Primary Indications * Complicated intra-abdominal infections * Complicated skin and skin structure infections * Community-acquired pneumonia * Nosocomial pneumonia * Febrile neutropenia (empiric treatment) ## Adult Dosing Standard dose is 3.375 g (3 g piperacillin/0.375 g tazobactam) or 4.5 g (4 g piperacillin/0.5 g tazobactam) IV every 6 or 8 hours. Duration of therapy is typically 7-14 days, guided by clinical response and local resistance patterns. For febrile neutropenia, the dose is often 4.5 g IV every 8 hours. ## Pediatric Dosing For patients 2 months of age and older: * **Intra-abdominal infection:** 90-100 mg piperacillin component/kg/day divided every 6 or 8 hours. Maximum dose is 4.5 g per dose or 12 g/day. * **Complicated skin and skin structure infections:** 100 mg piperacillin component/kg/day divided every 8 hours. Maximum dose is 4.5 g per dose or 12 g/day. * **Community-acquired pneumonia:** 100 mg piperacillin component/kg/day divided every 8 hours. Maximum dose is 4.5 g per dose or 12 g/day. * **Febrile neutropenia:** 100 mg piperacillin component/kg/day divided every 8 hours. Maximum dose is 4.5 g per dose or 12 g/day. **Note:** For neonates and infants younger than 2 months, dosing should be based on institutional protocols due to immature renal and hepatic function. ## Dose Adjustments * **Renal Impairment:** * CrCl > 40 mL/min: No dose adjustment. * CrCl 20-40 mL/min: Administer usual dose every 8 hours. * CrCl < 20 mL/min: Administer usual dose every 12 hours. * Hemodialysis: Administer usual dose every 12 hours and supplement with 1.5 g after each dialysis session. * **Hepatic Impairment:** No specific dose adjustment is usually recommended, but caution is advised. ## Contraindications * Known hypersensitivity to piperacillin, tazobactam, other penicillins, or beta-lactamase inhibitors. * History of cholestatic jaundice or hepatic dysfunction associated with piperacillin-tazobactam. ## Adverse Effects Common: Diarrhea, rash, nausea, vomiting, headache, insomnia, pruritus, urticaria. Serious: *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), seizures (rare, typically with high doses or renal impairment), liver enzyme elevations. ## Key Drug Interactions * **Probenecid:** May increase and prolong piperacillin-tazobactam plasma concentrations. * **Neuromuscular blocking agents:** Piperacillin may prolong the action of vecuronium. * **Oral anticoagulants (e.g., warfarin):** May affect INR. Monitor INR closely. * **Methotrexate:** Penicillins may decrease methotrexate clearance, leading to increased toxicity. ## Monitoring * Renal function (especially in patients with pre-existing renal disease or those receiving nephrotoxic agents). * Liver function tests. * Signs and symptoms of hypersensitivity reactions. * Signs and symptoms of *C. difficile* infection. * Electrolytes. * INR if on concomitant anticoagulation. ## Clinical Pearls * Administer by IV infusion over at least 30 minutes. Do not administer as an IV bolus. * Reconstituted solutions should be used within 24 hours when refrigerated or within 12 hours at room temperature. * Tazobactam protects piperacillin from degradation by many beta-lactamases, extending its spectrum of activity. * The presence of piperacillin may significantly reduce the incidence of PBP3-mediated resistance to tazobactam. * Monitor for potential development of resistance during prolonged therapy. *** *This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant guidelines for complete and up-to-date details before making any clinical decisions.*